sulfotransferase family 4A member 1Genealiases: BR-STL-1 · BRSTL1 · DJ388M5.3 · NST · SULTX3 · hBR-STL-1
Q-omics provides the consensus-scored SULT4A1 profile across patient tissues and cancer cell-line models. SULT4A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SULT4A1 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, SULT4A1 RNA expression shows 15,831 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, KIRP, and GBM as cancer lineages where SULT4A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT4A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT4A1 survival associations across molecular data types. SULT4A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT4A1 RNA expression–survival associations across cancer types. High SULT4A1 expression shows unfavorable associations in OV, KIRC, CESC and ACC, but favorable associations in LUAD and UVM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for SULT4A1 RNA expression.
This table summarizes SULT4A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SULT4A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT4A1 shows lower tumor expression in COAD and higher tumor expression in KIRP, LUAD, LIHC, THCA and LUSC. The KIRP box plot shows higher SULT4A1 RNA expression in tumor versus normal tissue (log2 FC = +1.667, t-test p < 0.001).
This table shows molecular features associated with SULT4A1 in patient tissues and cancer cell lines. In patient samples, SULT4A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT4A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
